<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
   <front>
      <journal-meta>
         <journal-id journal-id-type="publisher-id">DIJ</journal-id>
         <journal-id journal-id-type="hwp">spdij</journal-id>
         <journal-title>Drug Information Journal</journal-title>
         <issn pub-type="ppub">0092-8615</issn>
         <publisher>
            <publisher-name>SAGE Publications</publisher-name>
            <publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
         </publisher>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="doi">10.1177/0092861512450568</article-id>
         <article-id pub-id-type="publisher-id">10.1177_0092861512450568</article-id>
         <article-categories>
            <subj-group subj-group-type="heading">
               <subject>Drug Information</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title>Quality Standards for Antiretrovirals in <italic>Indian Pharmacopoeia</italic>
            </article-title>
         </title-group>
         <contrib-group>
            <contrib contrib-type="author" corresp="yes" xlink:type="simple">
               <name name-style="western">
                  <surname>Vivekanandan</surname>
                  <given-names>Kalaiselvan</given-names>
               </name>
               <degrees>MPharm, PhD</degrees>
               <xref ref-type="aff" rid="aff1-0092861512450568">1</xref>
               <xref ref-type="corresp" rid="corresp1-0092861512450568"/>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Sharma</surname>
                  <given-names>Hemant</given-names>
               </name>
               <degrees>MPharm</degrees>
               <xref ref-type="aff" rid="aff1-0092861512450568">1</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Singh</surname>
                  <given-names>Gyanendra Nath</given-names>
               </name>
               <degrees>MPharm, PhD</degrees>
               <xref ref-type="aff" rid="aff1-0092861512450568">1</xref>
            </contrib>
            <aff id="aff1-0092861512450568">
               <label>1</label>Indian Pharmacopoeia Commission, Ministry of Health and Family Welfare, Government of India, Ghaziabad, India</aff>
         </contrib-group>
         <author-notes>
            <corresp id="corresp1-0092861512450568">Kalaiselvan Vivekanandan, MPharm, PhD, Indian Pharmacopoeia Commission, Ministry of Health and Family Welfare, Government of India, Sector 23, Rajnagar, Ghaziabad, UP, 201 002, India Email: <email xlink:type="simple">vivekarts@rediffmail.com</email>
            </corresp>
         </author-notes>
         <pub-date pub-type="epub-ppub">
            <month>9</month>
            <year>2012</year>
         </pub-date>
         <volume>46</volume>
         <issue>5</issue>
         <fpage>581</fpage>
         <lpage>586</lpage>
         <history>
            <date date-type="received">
               <day>17</day>
               <month>2</month>
               <year>2012</year>
            </date>
            <date date-type="accepted">
               <day>13</day>
               <month>5</month>
               <year>2012</year>
            </date>
         </history>
         <permissions>
            <copyright-statement>© The Author(s) 2012</copyright-statement>
            <copyright-year>2012</copyright-year>
            <copyright-holder content-type="society">Drug Information Association</copyright-holder>
         </permissions>
         <abstract>
            <p>The global antiretroviral market is expanding dramatically with the approval of competent authorities in individual countries. In India, the Central Drugs Standard Control Organization (CDSCO) and Indian Pharmacopoeia Commission (IPC) are making efforts to approve and set the standards for antiretroviral drugs, respectively. The IPC publishes an official book of standards known as <italic>Indian Pharmacopoeia</italic> (<italic>IP</italic>) in fulfillment of the requirements of the Drugs and Cosmetics Act of 1940. There are 41 antiretroviral active pharmaceutical ingredients (APIs) and combinations approved by the CDSCO; the sixth edition of <italic>IP</italic> contains 52 monographs of different APIs and formulations. The monographs of antiretrovirals include descriptions, identifications, impurities, assays, and specific tests. <italic>IP</italic> plays a significant role in improving the quality of antiretroviral drugs, which in turn promote public health.</p>
         </abstract>
         <kwd-group>
            <kwd>antiretrovirals</kwd>
            <kwd>Indian Pharmacopoeia Commission</kwd>
            <kwd>
               <italic>Indian Pharmacopoeia</italic>
            </kwd>
            <kwd>monograph</kwd>
            <kwd>Central Drugs Standard Control Organization</kwd>
         </kwd-group>
      </article-meta>
   </front>
   <body>
      <sec id="section1-0092861512450568">
         <title>Introduction</title>
         <p>India has emerged as a world leader in the production of generic pharmaceuticals, contributing 20% of the global market for generic medicines, and more than 80% of all donor-funded antiretrovirals purchased since 2006 were supplied by Indian generic manufacturers.<sup>
               <xref ref-type="bibr" rid="bibr1-0092861512450568">1</xref>
            </sup> From 2002 to 2008, more than 4 million people were started on antiretroviral therapy in developing countries.<sup>
               <xref ref-type="bibr" rid="bibr2-0092861512450568">2</xref>
            </sup> The current market for antiretrovirals is dominating; however, the use of substandard drugs poses threats to society, not only with regard to side effects but also in terms of trade relations, economic implications, and effects on global pandemics.<sup>
               <xref ref-type="bibr" rid="bibr3-0092861512450568">3</xref>
               <xref ref-type="bibr" rid="bibr4-0092861512450568"/>
               <xref ref-type="bibr" rid="bibr5-0092861512450568"/>
               <xref ref-type="bibr" rid="bibr6-0092861512450568"/>
               <xref ref-type="bibr" rid="bibr7-0092861512450568"/>–<xref ref-type="bibr" rid="bibr8-0092861512450568">8</xref>
            </sup> Furthermore, this is an issue that needs to be continually dealt with on the national and international policy levels.</p>
         <p>Various pharmacopoeial bodies are involved in this issue and try to set the standards for antiretroviral drugs. Pharmacopoeial standards and acceptance criteria are set with the intention that they be used only as compliance requirements and not as requirements to guarantee total quality assurance. Pharmacopoeial standards are the minimum with which a manufacturer must comply before release of a product for sale or distribution.</p>
         <p>To ensure the quality and standard of drugs in India, the Indian government’s Ministry of Health and Family Welfare publishes an official book of standards known as <italic>Indian Pharmacopoeia</italic> (<italic>IP</italic>) in fulfillment of the requirements of the Drugs and Cosmetics Act of 1940. <italic>IP</italic> is periodically published by the Indian Pharmacopoeia Commission (IPC), which is an autonomous institution also under the Ministry of Health and Family Welfare. <italic>IP</italic> makes an important contribution to public health by setting publicly available standards for the quality of medicines including antiretroviral drugs. This article describes the antiretroviral monographs and current quality standards set in <italic>IP</italic>.</p>
      </sec>
      <sec id="section2-0092861512450568">
         <title>Approval of Antiretroviral Drugs in India</title>
         <p>The Central Drugs Standard Control Organization (CDSCO) is a licensing authority (regulatory agency) for the approval of new drugs in India. The head office of the CDSCO is located in New Delhi and functions under the control of the Directorate General of Health Services, Ministry of Health and Family Welfare. The zonal offices of the CDSCO are located in Mumbai, Kolkata, Ghaziabad, and Chennai, with subzonal offices in Ahmadabad, Hyderabad, and 7 port offices. The CDSCO approved 41 antiretroviral APIs and their formulations during the years 2000 to 2010 for manufacturing and marketing in India.</p>
      </sec>
      <sec id="section3-0092861512450568">
         <title>Inclusion Criteria of Antiretroviral Monographs in <italic>IP</italic>
         </title>
         <p>To ensure the quality and standard of antiretroviral drugs (which are approved by the CDSCO for manufacturing and marketing) in the country, monographs of antiretroviral active pharmaceutical ingredients (APIs) and finished dosage formulations were incorporated in the fifth and sixth editions of <italic>IP</italic> 2007 and 2010, respectively (<xref ref-type="fig" rid="fig1-0092861512450568">Figure 1</xref>). An <italic>IP</italic> monograph of an antiretroviral includes the article definition, description, identification, packaging, storage, specifications, impurities, assay and specific tests, one or more analytical procedures for each test, acceptance criteria, other requirements, and so on.<sup>
               <xref ref-type="bibr" rid="bibr9-0092861512450568">9</xref>,<xref ref-type="bibr" rid="bibr10-0092861512450568">10</xref>
            </sup> The following criteria are applied to and incorporated within the antiretroviral monograph:</p>
         <fig id="fig1-0092861512450568" position="float">
            <label>Figure 1.</label>
            <caption>
               <p>Comparison of antiretroviral monographs in <italic>Indian Pharmacopoeia</italic> 2007 and 2010.</p>
            </caption>
            <graphic alt-version="no" position="float" xlink:href="10.1177_0092861512450568-fig1.tif" xlink:type="simple"/>
         </fig>
         <list list-type="bullet">
            <list-item>
               <p>drugs used in national health programs of India,</p>
            </list-item>
            <list-item>
               <p>drugs listed in the National List of Essential Medicines,</p>
            </list-item>
            <list-item>
               <p>drugs approved by the CDSCO (generics not less than 3),</p>
            </list-item>
            <list-item>
               <p>fixed drug combinations approved by the CDSCO and recommended by an IPC expert, and</p>
            </list-item>
            <list-item>
               <p>drugs considered appropriate by the IPC.</p>
            </list-item>
         </list>
      </sec>
      <sec id="section4-0092861512450568">
         <title>Quality Standards for Antiretroviral Monographs in <italic>IP</italic> 2010</title>
         <sec id="section5-0092861512450568">
            <title>Identification</title>
            <p>Many antiretroviral monographs in <italic>IP</italic> include identification tests using infrared spectroscopy, ultraviolet absorption spectrophotometry, thin layer chromatography, and high pressure liquid chromatography; these tests usually allow comparison either with a spectrum obtained from the reference substance or with a reference spectrum. Liquid chromatography is one of the newest and accurate methods for the identification and quantification of an unknown substance by comparing a reference chromatogram with the test chromatogram obtained in analysis.</p>
         </sec>
         <sec id="section6-0092861512450568">
            <title>Assay</title>
            <p>Simple and reliable methods to estimate antiretroviral drugs and their products are applied. In most cases, <italic>IP</italic> employed high pressure liquid chromatography, ultraviolet absorption spectrophotometry, and thin layer chromatography to estimate the content. There are few monographs (aciclovir intravenous infusion, aciclovir tablets) that are developed with ultraviolet methods in <italic>IP</italic>. The high pressure liquid chromatography method is widely employed in quality control assessment of drugs because of its sensitivity, repeatability, and specificity. On the other hand, the use of spectroscopic techniques can be considered a promising simple, faster, direct, and relatively less expensive alternative for the determination of active drug content in pharmaceutical formulations with sufficient reliability.<sup>
                  <xref ref-type="bibr" rid="bibr11-0092861512450568">11</xref>
               </sup> Both reference and test solutions are prepared and subjected to a chromatographic separation. Determinations are made using peak areas and peak heights. The test chromatogram obtained is compared with the reference chromatogram.</p>
         </sec>
         <sec id="section7-0092861512450568">
            <title>Related Substances</title>
            <p>Impurities in pharmaceuticals are the unwanted chemicals that remain with the APIs or that develop during formulation causing toxicity.<sup>
                  <xref ref-type="bibr" rid="bibr12-0092861512450568">12</xref>
               </sup> There are 2 types of impurities in medicines: impurities associated in active APIs and impurities created during a formulation. According to the guidelines of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), impurities associated with APIs are of 3 types:</p>
            <list list-type="bullet">
               <list-item>
                  <p>organic impurities (process and drug related),</p>
               </list-item>
               <list-item>
                  <p>inorganic impurities, and</p>
               </list-item>
               <list-item>
                  <p>residual solvents.</p>
               </list-item>
            </list>
            <p>Organic impurities may arise during the manufacturing process and/or storage of the new drug substance. They may be identified or unidentified, be volatile or nonvolatile, and include starting materials, by-products, intermediates, degradations, products, reagents, ligands, and catalysts.<sup>
                  <xref ref-type="bibr" rid="bibr13-0092861512450568">13</xref>
               </sup> Inorganic impurities may be derived from the drug manufacturing process and identified as reagents, ligands, inorganic salts, heavy metals, catalysts, filter aids, charcoal, and others. Residual solvents are the impurities present in the final product introduced with solvents.<sup>
                  <xref ref-type="bibr" rid="bibr14-0092861512450568">14</xref>,<xref ref-type="bibr" rid="bibr15-0092861512450568">15</xref>
               </sup> The ICH has also published guidelines for the validation of methods for analyzing impurities in new drug substances, products, residual solvents, and microbiological impurities.<sup>
                  <xref ref-type="bibr" rid="bibr16-0092861512450568">16</xref>,<xref ref-type="bibr" rid="bibr17-0092861512450568">17</xref>
               </sup>
            </p>
         </sec>
      </sec>
      <sec id="section8-0092861512450568">
         <title>
            <italic>IP</italic> Status on Impurities in Antiretroviral Drugs</title>
         <p>The adequate control of impurities in antiretroviral monographs in <italic>IP</italic> is ensuring the protection of public health. The quality of an antiretroviral drug substance with respect to various impurities is controlled by a set of tests within a monograph. Individual monographs in <italic>IP</italic> 2007 and 2010 are periodically updated to keep pace with analytical developments and regulatory requirements (<xref ref-type="table" rid="table1-0092861512450568">Table 1</xref>). A general chapter concerning the control of impurities in pharmaceutical substances was introduced in the sixth edition of <italic>IP</italic>. It provides an approach to the setting of limits for impurities in articles for which the individual monographs do not provide either a test or specific limits. The exclusion of a limit for impurities in a monograph does not absolve the manufacturer from providing assurance to the user on the safety of a drug. It is incumbent on the manufacturer to follow Good Manufacturing Practices and to ensure the limitation of impurities based on knowledge of the properties of the chemical entity and the likelihood of related substances being associated with the end product during production and subsequent storage.</p>
         <table-wrap id="table1-0092861512450568" position="float">
            <label>Table 1.</label>
            <caption>
               <p>Impurity profiling of antiretroviral monographs in <italic>Indian Pharmacopoeia</italic> (<italic>IP</italic>) 2010.</p>
            </caption>
            <graphic alt-version="no" alternate-form-of="table1-0092861512450568" position="float" xlink:href="10.1177_0092861512450568-table1.tif" xlink:type="simple"/>
            <table>
               <thead>
                  <tr>
                     <th colspan="1" rowspan="2">Name of Monograph</th>
                     <th colspan="2" rowspan="1">Related Substances in <italic>IP</italic>
                     </th>
                  </tr>
                  <tr>
                     <th colspan="1" rowspan="1">Name of Impurity</th>
                     <th colspan="1" rowspan="1">Limit</th>
                  </tr>
               </thead>
               <tbody>
                  <tr>
                     <td colspan="1" rowspan="1">Abacavir sulfate</td>
                     <td colspan="1" rowspan="1">Total impurities</td>
                     <td colspan="1" rowspan="1">NMT 5%</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Abacavir oral solution</td>
                     <td colspan="1" rowspan="1">—</td>
                     <td colspan="1" rowspan="1">—</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Abacavir tablets</td>
                     <td colspan="1" rowspan="1">—</td>
                     <td colspan="1" rowspan="1">—</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Abacavir + lamivudine tablets</td>
                     <td colspan="1" rowspan="1">—</td>
                     <td colspan="1" rowspan="1">—</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Abacavir + lamivudine + zidovudine tablets</td>
                     <td colspan="1" rowspan="1">—</td>
                     <td colspan="1" rowspan="1">—</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Aciclovir</td>
                     <td colspan="1" rowspan="1">Total impurities</td>
                     <td colspan="1" rowspan="1">NMT 0.5%</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Aciclovir intravenous infusion</td>
                     <td colspan="1" rowspan="1">—</td>
                     <td colspan="1" rowspan="1">—</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Aciclovir tablets</td>
                     <td colspan="1" rowspan="1">Total impurities </td>
                     <td colspan="1" rowspan="1">NMT 0.7%</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Atazanavir sulfate</td>
                     <td colspan="1" rowspan="1">Total impurities</td>
                     <td colspan="1" rowspan="1">NMT 1%</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Atazanavir capsules</td>
                     <td colspan="1" rowspan="1">Total impurities </td>
                     <td colspan="1" rowspan="1">NMT 2%</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Didanosine</td>
                     <td colspan="1" rowspan="1">Total impurities</td>
                     <td colspan="1" rowspan="1">NMT 1%</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Didanosine capsules</td>
                     <td colspan="1" rowspan="1">Total impurities</td>
                     <td colspan="1" rowspan="1">NMT 5.5%</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Didanosine tablets</td>
                     <td colspan="1" rowspan="1">Total impurities </td>
                     <td colspan="1" rowspan="1">NMT 6%</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Efavirenz</td>
                     <td colspan="1" rowspan="1">Total impurities</td>
                     <td colspan="1" rowspan="1">NMT 1%</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Efavirenz capsules</td>
                     <td colspan="1" rowspan="1">Total impurities</td>
                     <td colspan="1" rowspan="1">NMT 2%</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Efavirenz tablets</td>
                     <td colspan="1" rowspan="1">Total impurities</td>
                     <td colspan="1" rowspan="1">NMT 2%</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Emtricitabine</td>
                     <td colspan="1" rowspan="1">Total impurities</td>
                     <td colspan="1" rowspan="1">NMT 2%</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Emtricitabine capsules</td>
                     <td colspan="1" rowspan="1">Total impurities</td>
                     <td colspan="1" rowspan="1">NMT 3%</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Indinavir sulfate</td>
                     <td colspan="1" rowspan="1">Monoethyl sulfate</td>
                     <td colspan="1" rowspan="1">NMT 0.5%</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Indinavir capsules</td>
                     <td colspan="1" rowspan="1">Total impurities</td>
                     <td colspan="1" rowspan="1">NMT 2.5%</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Lamivudine</td>
                     <td colspan="1" rowspan="1">Total impurities</td>
                     <td colspan="1" rowspan="1">NMT 1%</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Lamivudine oral solution</td>
                     <td colspan="1" rowspan="1">Total impurities</td>
                     <td colspan="1" rowspan="1">NMT 2%</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Lamivudine tablets</td>
                     <td colspan="1" rowspan="1">Total impurities</td>
                     <td colspan="1" rowspan="1">NMT 2%</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Lamivudine + tenofovir tablets</td>
                     <td colspan="1" rowspan="1">Total impurities</td>
                     <td colspan="1" rowspan="1">NMT 6%</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Lamivudine + zidovudine tablets</td>
                     <td colspan="1" rowspan="1">Total impurities</td>
                     <td colspan="1" rowspan="1">NMT 3%</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Lamivudine + nevirapine + stavudine dispersible tablets</td>
                     <td colspan="1" rowspan="1">Total impurities</td>
                     <td colspan="1" rowspan="1">NMT 5%</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Lamivudine + nevirapine + stavudine tablets</td>
                     <td colspan="1" rowspan="1">Total impurities</td>
                     <td colspan="1" rowspan="1">NMT 3.5%</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Nelfinavir mesylate</td>
                     <td colspan="1" rowspan="1">Methanesulfonic acid</td>
                     <td colspan="1" rowspan="1">NMT 1%</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Nelfinavir mesylate oral powder</td>
                     <td colspan="1" rowspan="1">Total impurities</td>
                     <td colspan="1" rowspan="1">NMT 2%</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Nelfinavir tablets</td>
                     <td colspan="1" rowspan="1">Methanesulfonic acid</td>
                     <td colspan="1" rowspan="1">NMT 2%</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Nevirapine</td>
                     <td colspan="1" rowspan="1">Total impurities</td>
                     <td colspan="1" rowspan="1">NMT 1%</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Nevirapine oral suspension</td>
                     <td colspan="1" rowspan="1">Total impurities</td>
                     <td colspan="1" rowspan="1">NMT 2%</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Nevirapine tablets</td>
                     <td colspan="1" rowspan="1">Total impurities</td>
                     <td colspan="1" rowspan="1">NMT 2%</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Ritonavir</td>
                     <td colspan="1" rowspan="1">Total impurities</td>
                     <td colspan="1" rowspan="1">NMT 1%</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Ritonavir capsules</td>
                     <td colspan="1" rowspan="1">Total impurities</td>
                     <td colspan="1" rowspan="1">NMT 5%</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Ritonavir tablets</td>
                     <td colspan="1" rowspan="1">Total impurities</td>
                     <td colspan="1" rowspan="1">NMT 5%</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Saquinavir</td>
                     <td colspan="1" rowspan="1">Total impurities</td>
                     <td colspan="1" rowspan="1">NMT 0.5%</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Saquinavir mesylate</td>
                     <td colspan="1" rowspan="1">Methanesulfonic acid</td>
                     <td colspan="1" rowspan="1">NMT 0.5%</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Saquinavir mesylate tablets</td>
                     <td colspan="1" rowspan="1">Total impurities</td>
                     <td colspan="1" rowspan="1">NMT 1%</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Stavudine</td>
                     <td colspan="1" rowspan="1">Total impurities</td>
                     <td colspan="1" rowspan="1">NMT 1%</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Stavudine capsules</td>
                     <td colspan="1" rowspan="1">Total impurities</td>
                     <td colspan="1" rowspan="1">NMT 4%</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Stavudine oral solution</td>
                     <td colspan="1" rowspan="1">Total impurities</td>
                     <td colspan="1" rowspan="1">NMT 3%</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Stavudine + lamivudine tablets</td>
                     <td colspan="1" rowspan="1">Total impurities</td>
                     <td colspan="1" rowspan="1">NMT 4%</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Tenofovir disoproxil fumarate</td>
                     <td colspan="1" rowspan="1">Fumaric acid</td>
                     <td colspan="1" rowspan="1">NMT 0.2%</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Tenofovir disoproxil fumarate tablets</td>
                     <td colspan="1" rowspan="1">Total impurities</td>
                     <td colspan="1" rowspan="1">NMT 6%</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Tenofovir + emtricitabine tablets</td>
                     <td colspan="1" rowspan="1">Total impurities</td>
                     <td colspan="1" rowspan="1">NMT 6%</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Zidovudine</td>
                     <td colspan="1" rowspan="1">Total impurities</td>
                     <td colspan="1" rowspan="1">NMT 3%</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Zidovudine capsules</td>
                     <td colspan="1" rowspan="1">Total impurities</td>
                     <td colspan="1" rowspan="1">NMT 3%</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Zidovudine injection</td>
                     <td colspan="1" rowspan="1">Total impurities</td>
                     <td colspan="1" rowspan="1">NMT 2%</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Zidovudine oral solution</td>
                     <td colspan="1" rowspan="1">Total impurities</td>
                     <td colspan="1" rowspan="1">NMT 3%</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Zidovudine tablets</td>
                     <td colspan="1" rowspan="1">Total impurities</td>
                     <td colspan="1" rowspan="1">NMT 2%</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Zidovudine + lamivudine + nevirapine tablets</td>
                     <td colspan="1" rowspan="1">Total impurities</td>
                     <td colspan="1" rowspan="1">NMT 2.5%</td>
                  </tr>
               </tbody>
            </table>
            <table-wrap-foot>
               <fn id="table-fn1-0092861512450568">
                  <p>NMT, not more than.</p>
               </fn>
            </table-wrap-foot>
         </table-wrap>
         <p>Validated analytical methods can be applied in determining the limits of detection and quantitation. The most widely used methodology is chromatography, which is the basis of the test for related substances. In chromatographic determinations, in the absence of a reference substance, it is usual practice to limit the levels of impurities by the simple test of comparison of the unknown spot or peak with a spot or peak obtained with a dilute solution of the substance under examination. Thin layer chromatography and gas chromatography are used to determine the impurities.</p>
      </sec>
      <sec id="section9-0092861512450568">
         <title>Other Tests</title>
         <sec id="section10-0092861512450568">
            <title>Water Content</title>
            <p>Water is widely used in the processing of antiretroviral APIs and formulations as a solvent.<sup>
                  <xref ref-type="bibr" rid="bibr18-0092861512450568">18</xref>
               </sup> 
               <italic>IP</italic> specifies Karl Fischer titration, azeotropic distillation, and coulometric titration to measure the water content in antiretrovirals.</p>
         </sec>
         <sec id="section11-0092861512450568">
            <title>Heavy Metals</title>
            <p>The most common heavy metals that humans are exposed to and that induce their toxic effects are arsenic, cadmium, lead, and mercury.<sup>
                  <xref ref-type="bibr" rid="bibr19-0092861512450568">19</xref>,<xref ref-type="bibr" rid="bibr20-0092861512450568">20</xref>
               </sup> The limit test (method A or method B) for heavy metals given in <italic>IP</italic> is to demonstrate that the content of metallic impurities that are colored by hydrogen sulfide does not exceed the heavy metals limit given in the individual monograph in terms of parts per million.</p>
         </sec>
         <sec id="section12-0092861512450568">
            <title>Sulfated Ash</title>
            <p>The sulfated ash test is applied to measure the amount of residual substance (nonvolatile) from a sample when the test substance is ignited in the presence of sulfuric acid. It is determined as per method B in <italic>IP</italic> 2010. The limit for water content, heavy metals, and sulfated ash for antiretrovirals is indicated in <xref ref-type="table" rid="table2-0092861512450568">Table 2</xref>.</p>
            <table-wrap id="table2-0092861512450568" position="float">
               <label>Table 2.</label>
               <caption>
                  <p>Limit of water content, heavy metals, and sulfated ash for antiretroviral monographs in <italic>Indian Pharmacopoeia</italic> 2010.</p>
               </caption>
               <graphic alt-version="no" alternate-form-of="table2-0092861512450568" position="float" xlink:href="10.1177_0092861512450568-table2.tif" xlink:type="simple"/>
               <table>
                  <thead>
                     <tr>
                        <th colspan="1" rowspan="1">Name of Monograph</th>
                        <th colspan="1" rowspan="1">Water Content</th>
                        <th colspan="1" rowspan="1">Heavy Metals</th>
                        <th colspan="1" rowspan="1">Sulfated Ash</th>
                     </tr>
                  </thead>
                  <tbody>
                     <tr>
                        <td colspan="1" rowspan="1">Abacavir sulfate</td>
                        <td colspan="1" rowspan="1">NMT 1.5%</td>
                        <td colspan="1" rowspan="1">20 ppm (method B)</td>
                        <td colspan="1" rowspan="1">NMT 0.3%</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">Abacavir tablets</td>
                        <td colspan="1" rowspan="1">NMT 5%</td>
                        <td align="center" colspan="1" rowspan="1">—</td>
                        <td align="center" colspan="1" rowspan="1">—</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">Abacavir oral solution</td>
                        <td colspan="1" rowspan="1">NMT 3%</td>
                        <td align="center" colspan="1" rowspan="1">—</td>
                        <td align="center" colspan="1" rowspan="1">—</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">Aciclovir </td>
                        <td colspan="1" rowspan="1">NMT 6%</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">NMT 0.1%</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">Atazanavir sulfate</td>
                        <td align="center" colspan="1" rowspan="1">—</td>
                        <td colspan="1" rowspan="1">20 ppm (method A)</td>
                        <td colspan="1" rowspan="1">NMT 0.1%</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">Didanosine </td>
                        <td align="center" colspan="1" rowspan="1">—</td>
                        <td colspan="1" rowspan="1">20 ppm (method A)</td>
                        <td colspan="1" rowspan="1">NMT 0.2%</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">Efavirenz</td>
                        <td align="center" colspan="1" rowspan="1">—</td>
                        <td colspan="1" rowspan="1">20 ppm (method B)</td>
                        <td colspan="1" rowspan="1">NMT 0.1%</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">Emtricitabine</td>
                        <td align="center" colspan="1" rowspan="1">—</td>
                        <td colspan="1" rowspan="1">20 ppm (method B)</td>
                        <td colspan="1" rowspan="1">NMT 0.1%</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">Emtricitabine capsules</td>
                        <td colspan="1" rowspan="1">NMT 5%</td>
                        <td align="center" colspan="1" rowspan="1">—</td>
                        <td align="center" colspan="1" rowspan="1">—</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">Indinavir sulfate</td>
                        <td colspan="1" rowspan="1">NMT 1.5%</td>
                        <td colspan="1" rowspan="1">20 ppm (method B)</td>
                        <td colspan="1" rowspan="1">NMT 0.1%</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">Lamivudine </td>
                        <td colspan="1" rowspan="1">NMT 0.5%</td>
                        <td colspan="1" rowspan="1">20 ppm (method B)</td>
                        <td colspan="1" rowspan="1">NMT 0.2%</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">Nelfinavir mesylate</td>
                        <td colspan="1" rowspan="1">NMT 3%</td>
                        <td colspan="1" rowspan="1">20 ppm (method B)</td>
                        <td colspan="1" rowspan="1">NMT 0.1%</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">Nelfinavir mesylate oral powder</td>
                        <td colspan="1" rowspan="1">NMT 12%</td>
                        <td align="center" colspan="1" rowspan="1">—</td>
                        <td align="center" colspan="1" rowspan="1">—</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">Nelfinavir tablets</td>
                        <td align="center" colspan="1" rowspan="1">—</td>
                        <td align="center" colspan="1" rowspan="1">—</td>
                        <td align="center" colspan="1" rowspan="1">—</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">Nevirapine </td>
                        <td align="center" colspan="1" rowspan="1">—</td>
                        <td colspan="1" rowspan="1">20 ppm (method B)</td>
                        <td colspan="1" rowspan="1">NMT 0.2%</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">Ritonavir</td>
                        <td colspan="1" rowspan="1">NMT 0.5%</td>
                        <td colspan="1" rowspan="1">20 ppm (method B)</td>
                        <td colspan="1" rowspan="1">NMT 0.1%</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">Saquinavir</td>
                        <td colspan="1" rowspan="1">NMT 2%</td>
                        <td colspan="1" rowspan="1">10 ppm (method B)</td>
                        <td colspan="1" rowspan="1">
</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">Saquinavir mesylate tablets</td>
                        <td colspan="1" rowspan="1">NMT 6%</td>
                        <td align="center" colspan="1" rowspan="1">—</td>
                        <td align="center" colspan="1" rowspan="1">—</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">Saquinavir mesylate</td>
                        <td colspan="1" rowspan="1">NMT 1%</td>
                        <td align="center" colspan="1" rowspan="1">—</td>
                        <td colspan="1" rowspan="1">NMT 0.1%</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">Stavudine</td>
                        <td align="center" colspan="1" rowspan="1">—</td>
                        <td colspan="1" rowspan="1">20 ppm (method B)</td>
                        <td colspan="1" rowspan="1">NMT 0.3%</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">Stavudine + lamivudine tablets</td>
                        <td align="center" colspan="1" rowspan="1">—</td>
                        <td align="center" colspan="1" rowspan="1">—</td>
                        <td align="center" colspan="1" rowspan="1">—</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">Stavudine oral solution </td>
                        <td colspan="1" rowspan="1">NMT 2%</td>
                        <td align="center" colspan="1" rowspan="1">—</td>
                        <td align="center" colspan="1" rowspan="1">—</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">Tenofovir disoproxil fumarate</td>
                        <td colspan="1" rowspan="1">NMT 1%</td>
                        <td align="center" colspan="1" rowspan="1">—</td>
                        <td align="center" colspan="1" rowspan="1">—</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">Tenofovir disoproxil fumarate tablets</td>
                        <td colspan="1" rowspan="1">NMT 5%</td>
                        <td align="center" colspan="1" rowspan="1">—</td>
                        <td align="center" colspan="1" rowspan="1">—</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">Zidovudine </td>
                        <td colspan="1" rowspan="1">NMT 1%</td>
                        <td colspan="1" rowspan="1">20 ppm (method B)</td>
                        <td colspan="1" rowspan="1">NMT 0.25%</td>
                     </tr>
                  </tbody>
               </table>
               <table-wrap-foot>
                  <fn id="table-fn2-0092861512450568">
                     <p>NMT, not more than.</p>
                  </fn>
               </table-wrap-foot>
            </table-wrap>
         </sec>
      </sec>
      <sec id="section13-0092861512450568">
         <title>Reference Substance</title>
         <p>Reference substance is the basis for the quality control of medicines and is the benchmark for the assessment of drug safety.<sup>
               <xref ref-type="bibr" rid="bibr21-0092861512450568">21</xref>
            </sup> The <italic>IP</italic> official reference substance for antiretroviral drugs is highly characterized specimens, and its establishment is also an essential part of quality control. They are designated for use in identification tests, limit tests for impurities or related compounds, assays for APIs and for formulations, system suitability tests, chromatographic and spectrophotometric procedures, performance verification tests as calibrators, blanks, and controls. The IPC made available 10 more commonly required antiretroviral reference substances to the stakeholders.</p>
      </sec>
      <sec id="section14-0092861512450568">
         <title>Contribution of <italic>IP</italic> in Antiretroviral Therapy</title>
         <p>During the last 11 years, there have been 41 APIs and combinations of antiretrovirals approved for marketing in India by the CDSCO; <italic>IP</italic> 2010 contains 52 monographs of different antiretroviral APIs and their formulations. This has allowed the availability of quality antiretrovirals at affordable prices for a large number of people in the country. Most of the antiretroviral standards in <italic>IP</italic> are harmonized with international acceptance criteria for drug quality.</p>
      </sec>
      <sec id="section15-0092861512450568">
         <title>Challenges and Future Directions</title>
         <p>The major challenges and future direction for <italic>IP</italic> toward the development of antiretroviral monographs are as follows:</p>
         <list list-type="bullet">
            <list-item>
               <p>In the current edition of <italic>IP</italic>, only few monographs have developed the method to detect specific impurities, whereas other monographs emphasize total impurities. Hence, it is a major challenge to specify the limit of separate impurities and to develop identification methods.</p>
            </list-item>
            <list-item>
               <p>To provide authoritative monographs for antiretroviral drugs available in the Indian market, there is a need to add more numbers in the next edition of <italic>IP</italic>.</p>
            </list-item>
            <list-item>
               <p>Assay methods for antiretroviral monographs would be upgraded by high pressure liquid chromatography/liquid chromatography mass spectrometry.</p>
            </list-item>
            <list-item>
               <p>The IPC is continuing in the establishment of a reference substance for antiretroviral drugs. The reference substance, used together with monographs, is needed for quality control testing.</p>
            </list-item>
            <list-item>
               <p>As the global market for antiretroviral drugs increases, the move toward harmonized requirements for antiretroviral monographs depends on a consensus view of the purpose and scope of their contents, especially for the development of the 4 main elements: identification, characterization, control of impurities, and assay of antiretroviral APIs and their formulations.</p>
            </list-item>
         </list>
      </sec>
      <sec id="section16-0092861512450568">
         <title>Conclusions</title>
         <p>
            <italic>IP</italic> standards for antiretroviral drugs and their formulations are published periodically to help manufacturers as well as regulators by providing fundamental requirements and a “common ground” for making a standard drug, which allows practitioners to have confidence in the medicines they prescribe and patients in the medicines they take. <italic>IP</italic> plays a crucial role in the development of quality standard monographs for antiretroviral drugs, and generic antiretroviral manufacturers can play a significant role in the global treatment of HIV/AIDS.</p>
      </sec>
   </body>
   <back>
      <fn-group>
         <fn fn-type="conflict" id="fn1-0092861512450568">
            <label>Declaration of Conflicting Interests</label>
            <p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. </p>
         </fn>
         <fn fn-type="financial-disclosure" id="fn2-0092861512450568">
            <label>Funding</label>
            <p>The author(s) received no financial support for the research, authorship, and/or publication of this article. </p>
         </fn>
      </fn-group>
      <ref-list>
         <title>References</title>
         <ref id="bibr1-0092861512450568">
            <label>1</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Waning</surname>
                     <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Diedrichsen</surname>
                     <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Moon</surname>
                     <given-names>S</given-names>
                  </name>
               </person-group>. <article-title>A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries</article-title>. <source>J Int AIDS Soc</source>. <year>2010</year>;<volume>13</volume>:<fpage>13</fpage>–<lpage>35</lpage>.</citation>
         </ref>
         <ref id="bibr2-0092861512450568">
            <label>2</label>
            <citation citation-type="book" xlink:type="simple">
               <collab collab-type="author" xlink:type="simple">
                  <italic>World Health Organization</italic>
               </collab>. <source>Towards Universal Access: Scaling Up Priority HIV/AIDS Interventions in the Health Sector</source>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name>; <year>2009</year>.</citation>
         </ref>
         <ref id="bibr3-0092861512450568">
            <label>3</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Nsimba</surname>
                     <given-names>SE</given-names>
                  </name>
               </person-group>. <article-title>Problems associated with substandard and counterfeit drugs in developing countries: a review article on global implications of counterfeit drugs in the era of antiretroviral (ARVs) drugs in a free market economy</article-title>. <source>East Afr J Public Health</source>. <year>2008</year>;<volume>5</volume>:<fpage>205</fpage>–<lpage>210</lpage>.</citation>
         </ref>
         <ref id="bibr4-0092861512450568">
            <label>4</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Caudron</surname>
                     <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Ford</surname>
                     <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Henkens</surname>
                     <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Mace</surname>
                     <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Kiddle-Monroe</surname>
                     <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Pinel</surname>
                     <given-names>J</given-names>
                  </name>
               </person-group>. <article-title>Substandard medicines in resource-poor settings: a problem that can no longer be ignored</article-title>. <source>Trop Med Int Health</source>. <year>2008</year>;<volume>13</volume>:<fpage>1062</fpage>–<lpage>1072</lpage>.</citation>
         </ref>
         <ref id="bibr5-0092861512450568">
            <label>5</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Gautam</surname>
                     <given-names>CS</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Utreja</surname>
                     <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Singal</surname>
                     <given-names>GL</given-names>
                  </name>
               </person-group>. <article-title>Spurious and counterfeit drugs: a growing industry in the developing world</article-title>. <source>Postgrad Med J</source>. <year>2009</year>;<volume>85</volume>:<fpage>251</fpage>–<lpage>256</lpage>.</citation>
         </ref>
         <ref id="bibr6-0092861512450568">
            <label>6</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Aldhous</surname>
                     <given-names>P</given-names>
                  </name>
               </person-group>. <article-title>Counterfeit pharmaceuticals: murder by medicine</article-title>. <source>Nature</source>. <year>2005</year>;<volume>434</volume>:<fpage>132</fpage>–<lpage>136</lpage>.</citation>
         </ref>
         <ref id="bibr7-0092861512450568">
            <label>7</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Newton</surname>
                     <given-names>PN</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Green</surname>
                     <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Fernandez</surname>
                     <given-names>FM</given-names>
                  </name>
               </person-group>. <article-title>Impact of poor-quality medicines in the developing world</article-title>. <source>Trends Pharmacol Sci</source>. <year>2010</year>;<volume>3</volume>:<fpage>99</fpage>–<lpage>101</lpage>.</citation>
         </ref>
         <ref id="bibr8-0092861512450568">
            <label>8</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Videau</surname>
                     <given-names>JY</given-names>
                  </name>
               </person-group>. <article-title>Quality of medicines in least developed countries</article-title>. <source>Med Trop (Maras)</source>. <year>2006</year>;<volume>66</volume>:<fpage>533</fpage>–<lpage>537</lpage>.</citation>
         </ref>
         <ref id="bibr9-0092861512450568">
            <label>9</label>
            <citation citation-type="book" xlink:type="simple">
               <collab collab-type="author" xlink:type="simple">
                  <italic>Ministry of Health and Family Welfare, Government of India</italic>
               </collab>. <source>Indian Pharmacopoeia</source>. <publisher-loc>Ghaziabad</publisher-loc>: <publisher-name>Indian Pharmacopoeia Commission</publisher-name>; <year>2010</year>.</citation>
         </ref>
         <ref id="bibr10-0092861512450568">
            <label>10</label>
            <citation citation-type="book" xlink:type="simple">
               <collab collab-type="author" xlink:type="simple">
                  <italic>Ministry of Health and Family Welfare, Government of India</italic>
               </collab>. <source>Indian Pharmacopoeia</source>. <publisher-loc>Ghaziabad</publisher-loc>: <publisher-name>Indian Pharmacopoeia Commission</publisher-name>; <year>2007</year>.</citation>
         </ref>
         <ref id="bibr11-0092861512450568">
            <label>11</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Mendez</surname>
                     <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Steppe</surname>
                     <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Schapoval</surname>
                     <given-names>E</given-names>
                  </name>
               </person-group>. <article-title>Stability and degradation kinetics of meropenem in powder for injection and reconstituted sample</article-title>. <source>J Pharm Biomed Anal</source>. <year>2006</year>;<volume>4</volume>:<fpage>1363</fpage>–<lpage>1366</lpage>.</citation>
         </ref>
         <ref id="bibr12-0092861512450568">
            <label>12</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Gorog</surname>
                     <given-names>S</given-names>
                  </name>
               </person-group>. <article-title>Chemical and analytical characterization of related organic impurities in drugs</article-title>. <source>Anal Bioanal Chem</source>. <year>2003</year>;<volume>377</volume>:<fpage>852</fpage>–<lpage>862</lpage>.</citation>
         </ref>
         <ref id="bibr13-0092861512450568">
            <label>13</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Qiu</surname>
                     <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Norwood</surname>
                     <given-names>DL</given-names>
                  </name>
               </person-group>. <article-title>Identification of pharmaceutical impurities</article-title>. <source>J Liq Chromatogr Relat Technol</source>. <year>2007</year>;<volume>30</volume>:<fpage>877</fpage>–<lpage>935</lpage>.</citation>
         </ref>
         <ref id="bibr14-0092861512450568">
            <label>14</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Rao</surname>
                     <given-names>RN</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Nagaraju</surname>
                     <given-names>V</given-names>
                  </name>
               </person-group>. <article-title>An overview of the recent trends in development of HPLC methods for determination of impurities in drugs</article-title>. <source>J Pharm Biomed Anal</source>. <year>2003</year>;<volume>33</volume>:<fpage>335</fpage>–<lpage>377</lpage>.</citation>
         </ref>
         <ref id="bibr15-0092861512450568">
            <label>15</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Rousseau</surname>
                     <given-names>G</given-names>
                  </name>
               </person-group>. <article-title>International Conference on Harmonisation impurity guidelines: the industry perspective</article-title>. <source>Drug Information Journal</source>. <year>2000</year>;<volume>34</volume>:<fpage>903</fpage>–<lpage>907</lpage>.</citation>
         </ref>
         <ref id="bibr16-0092861512450568">
            <label>16</label>
            <citation citation-type="journal" xlink:type="simple">
               <collab collab-type="author" xlink:type="simple">
                  <italic>International Conference on Harmonisation</italic>
               </collab>. <article-title>Q3A(R): Draft Revised Guidance on Impurities in New Drug Substances</article-title>. <source>Fed Regist</source>. <year>2000</year>;<volume>65</volume>(<issue>140</issue>):<fpage>45085</fpage>.</citation>
         </ref>
         <ref id="bibr17-0092861512450568">
            <label>17</label>
            <citation citation-type="journal" xlink:type="simple">
               <collab collab-type="author" xlink:type="simple">
                  <italic>International Conference on Harmonisation</italic>
               </collab>. <article-title>Q3B(R): Draft Revised Guidance on Impurities in New Drug Products</article-title>. <source>Fed Regist</source>. <year>2000</year>;<volume>65</volume>(<issue>139</issue>):<fpage>44791</fpage>.</citation>
         </ref>
         <ref id="bibr18-0092861512450568">
            <label>18</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Mallipeddi</surname>
                     <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Rohan</surname>
                     <given-names>LC</given-names>
                  </name>
               </person-group>. <article-title>Progress in antiretroviral drug delivery using nanotechnology</article-title>. <source>Int J Nanomed</source>. <year>2010</year>;<volume>5</volume>:<fpage>533</fpage>–<lpage>547</lpage>.</citation>
         </ref>
         <ref id="bibr19-0092861512450568">
            <label>19</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Flora</surname>
                     <given-names>SJS</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Mittal</surname>
                     <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Mehta</surname>
                     <given-names>A</given-names>
                  </name>
               </person-group>. <article-title>Heavy metal induced oxidative stress and its possible reversal by chelation therapy</article-title>. <source>Indian J Med Res</source>. <year>2008</year>;<volume>128</volume>:<fpage>501</fpage>–<lpage>523</lpage>.</citation>
         </ref>
         <ref id="bibr20-0092861512450568">
            <label>20</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Graeme</surname>
                     <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Pollack</surname>
                     <given-names>CV</given-names>
                     <suffix>Jr</suffix>
                  </name>
               </person-group>. <article-title>Heavy metal toxicity, part I: arsenic and mercury</article-title>. <source>J Emerg Med</source>. <year>1998</year>;<volume>16</volume>:<fpage>45</fpage>–<lpage>56</lpage>.</citation>
         </ref>
         <ref id="bibr21-0092861512450568">
            <label>21</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Sanjay</surname>
                     <given-names>BB</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Bharati</surname>
                     <given-names>RK</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Yogini</surname>
                     <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Atul</surname>
                     <given-names>AS</given-names>
                  </name>
               </person-group>. <article-title>Impurity profile: significance in active pharmaceutical ingredient</article-title>. <source>Eurasian J Anal Chem</source>. <year>2007</year>;<volume>2</volume>:<fpage>32</fpage>–<lpage>53</lpage>.</citation>
         </ref>
      </ref-list>
   </back>
</article>